Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low frequency of BRAF and CDKN2A mutations in endometrial cancer.

International journal of cancer - 20 Jul 2005

Salvesen Helga B, Kumar Rajiv, Stefansson Ingunn, Angelini Sabrina, MacDonald Nicola, Smeds Johanna, Jacobs Ian J, Hemminki Kari, Das Soma, Akslen Lars A

Abstract excerpt

Several pathways have been implicated in the pathogenesis of endometrial carcinoma. Based on recent reports, BRAF mutations provide an alternative route for activation of the RAS signalling pathway. The CDKN2A (p16) tumour suppressor gene is also altered in several tumour types. We therefore want...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRAF gene
Share to Endometrial Neoplasms
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p16

Share to Genes, ras

Share to Mutation

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 15723290
DOI: 10.1002/ijc.20702

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-15723290-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low frequency of BRAF and CDKN2A mutations in endometrial cancer.PMID 15723290Read ↗

P16/MTS1 and pRB expression in endometrial carcinomas.Semantic proximity Read ↗

Alteration of p16 and p15 genes in human uterine tumours.Semantic proximity Read ↗

p16/MTS1 inactivation in ovarian carcinomas: High frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumorsSemantic proximity Read ↗

Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordomaSemantic proximity Read ↗

BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression.Semantic proximity Read ↗

Inactivation of the p16INK4A gene by methylation is not a frequent event in sporadic ovarian carcinoma.Semantic proximity Read ↗

Mutations, methylation and expression of CDKN2a/p16 gene in colorectal cancer and normal colonic mucosa.Semantic proximity Read ↗

Alterations of the P16 gene in uterine cervical carcinoma from Indian patients.Semantic proximity Read ↗

Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.Semantic proximity Read ↗

Low frequency of CDKN2 mutation in endometrial carcinomas.Semantic proximity Read ↗

Allelic loss of chromosome 16q in endometrial cancer: correlation with poor prognosis of patients and less differentiated histology.Semantic proximity Read ↗

RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.